Department of Orthopedics, The Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, People's Republic of China.
Department of Pathology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, People's Republic of China.
BMC Cancer. 2023 Mar 10;23(1):229. doi: 10.1186/s12885-023-10688-7.
Osteosarcoma is a malignant tumor that usually occurs in adolescents aged 10-20 years and is associated with poor prognosis. Ferroptosis is an iron-dependent cell death mechanism that plays a vital role in cancer.
Osteosarcoma transcriptome data were downloaded from the public database TARGET and from previous studies. A prognostic risk score signature was constructed using bioinformatics analysis, and its efficacy was determined by analyzing typical clinical features. The prognostic signature was then validated with external data. Differences in immune cell infiltration between high- and low-risk groups were analyzed. The potential of the prognostic risk signature as a predictor of immunotherapy response was evaluated using the GSE35640 (melanoma) dataset. Five key genes expression were measured by real-time PCR and western blot in human normal osteoblasts and osteosarcoma cells. Moreover, malignant biological behaviors of osteosarcoma cells were tested by modulating gene expression level.
We obtained 268 ferroptosis-related genes from the online database FerrDb and published articles. Transcriptome data and clinical information of 88 samples in the TARGET database were used to classify genes into two categories using clustering analysis, and significant differences in survival status were identified. Differential ferroptosis-related genes were screened, and functional enrichment showed that they were associated with HIF-1, T cells, IL17, and other inflammatory signaling pathways. Prognostic factors were identified by univariate Cox regression and LASSO analysis, and a 5-factor prognostic risk score signature was constructed, which was also applicable for external data validation. Experimental validation indicated that the mRNA and protein expression level of MAP3K5, LURAP1L, HMOX1 and BNIP3 decreased significantly, though meanwhile MUC1 increased in MG-63 and SAOS-2 cells compared with hFOB1.19 cells. Cell proliferation and migration ability of SAOS-2 were affected based on alterations of signature genes.
Significant differences in immune cell infiltration between high- and low-risk groups indicated that the five ferroptosis-related prognostic signature was constructed and could be used to predict the response to immunotherapy in osteosarcoma.
骨肉瘤是一种常见于 10-20 岁青少年的恶性肿瘤,预后较差。铁死亡是一种铁依赖性的细胞死亡机制,在癌症中起着至关重要的作用。
从公共数据库 TARGET 和以前的研究中下载骨肉瘤转录组数据。使用生物信息学分析构建预后风险评分特征,并通过分析典型的临床特征来确定其疗效。然后用外部数据验证预后特征。分析高低风险组之间免疫细胞浸润的差异。使用 GSE35640(黑色素瘤)数据集评估预后风险特征作为免疫治疗反应预测因子的潜力。通过实时 PCR 和 Western blot 测量人正常成骨细胞和骨肉瘤细胞中五个关键基因的表达。此外,通过调节基因表达水平测试骨肉瘤细胞的恶性生物学行为。
我们从在线数据库 FerrDb 和已发表的文章中获得了 268 个与铁死亡相关的基因。使用聚类分析将 TARGET 数据库中 88 个样本的转录组数据和临床信息分为两类,发现生存状态存在显著差异。筛选差异表达的铁死亡相关基因,功能富集显示它们与 HIF-1、T 细胞、IL17 和其他炎症信号通路有关。通过单因素 Cox 回归和 LASSO 分析确定预后因素,并构建了一个 5 因素预后风险评分特征,也适用于外部数据验证。实验验证表明,与 hFOB1.19 细胞相比,MG-63 和 SAOS-2 细胞中 MAP3K5、LURAP1L、HMOX1 和 BNIP3 的 mRNA 和蛋白表达水平显著降低,而 MUC1 则增加。根据特征基因的改变,SAOS-2 细胞的增殖和迁移能力受到影响。
高低风险组之间免疫细胞浸润的显著差异表明,构建了 5 个与铁死亡相关的预后特征,可以用于预测骨肉瘤对免疫治疗的反应。